½ÃÀ庸°í¼
»óÇ°ÄÚµå
1273491
¼¼°èÀÇ ¹Ú¸· Á¦Á¦ ½ÃÀå : ¼ºÀå, µ¿Çâ, COVID-19ÀÇ ¿µÇâ, ¿¹Ãø(2023-2028³â)Thin Film Drugs Market - Growth, Trends, and Forecasts (2023 - 2028) |
¼¼°èÀÇ ¹Ú¸· Á¦Á¦(Thin Film Drugs) ½ÃÀåÀº ¾à 9.3%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
COVID-19´Â À¯Çà ±â°£¿¡ ½ÃÀå ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. COVID-19 Áúº´ Ä¡·á¸¦ À§ÇÑ Çõ½ÅÀûÀÌ°í ÷´Ü ±â¼ú Ãâ½Ã´Â ¹Ú¸· Á¦Ç° ¼ö¿ä¿¡ ÇöÀúÇÑ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 5¿ù, ¹Ú¸· µ¿°á ÀǾàÇ°Àº COVID-19 ¹× ±âŸ ¹ÙÀÌ·¯½º °¨¿°°ú ÀüÅõ ¹Ú¸· µ¿°á ±â¼úÀ» ÀÌ¿ëÇÑ Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×ü, ¹é½Å ¾ÈÁ¤È ¹× Àü´Þ¿¡ °üÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÏ´Â Ç÷§Æû ÇÁ·¹Á¨Å×À̼ÇÀ» ¹è´ÞÇß½À´Ï´Ù. ÀÌ¿Í °°ÀÌ À¯Çà ¹ß»ýÀº ÷´Ü ±â¼ú µµÀÔÀ¸·Î À̾îÁ® À¯Çà±â ½ÃÀå ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ¶ÇÇÑ, ´Ù¾çÇÑ ¸¸¼ºÁúȯ Ä¡·á ÁÖ¸ñµµ°¡ ³ô¾ÆÁö°í Àֱ⠶§¹®¿¡ ¹Ú¸· Á¦Á¦ ¼ö¿ä´Â °è¼Ó °ßÁ¶ÇÏ°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¾î ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù.
ÆíµÎÅë, Á¤½Å ºÐ¿Áõ, ¿ÀÇÇ¿ÀÀ̵å ÀÇÁ¸¼º°ú °°Àº Áúº´ À¯º´·ü Áõ°¡¿Í È¿°úÀûÀÎ ¹Ú¸· ¾à¹° ¿ÀÇÇ¿ÀÀÌµå ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î DN articleÀÌ 2022³â 1¿ù¿¡ ¹ßÇ¥ÇÑ ±â»ç¿¡ ÀÇÇϸé, ¼¼°è¿¡¼´Â ¸Å³â 7¸í Áß 1¸íÀÌ ÆíµÎÅëÀ¸·Î °íÅë¹Þ°í ÀÖÀ¸¸ç, 2021³â ¼¼°èÀÇ 14.7% »ç¶÷ÀÌ ÆíµÎÅëÀ» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¶Ç, ÀÌ ÀÚ·á´Â ¼¼°èÀÇ Àα¸ ¾à 2%°¡ ¸Å³â ¸¸¼ºÀûÀÎ ÆíµÎÅë¿¡ ½Ã´Þ¸®°í ÀÖ´Ù°í ¸»ÇÏ°í ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î 2022³â 6¿ù¿¡ ¹ßÇ¥µÈ NCBI ³í¹®¿¡ µû¸£¸é ¿ÀÇÇ¿ÀÀÌµå »ç¿ë Àå¾Ö´Â ¼¼°è¿¡¼ ¿¬°£ 1,600¸¸ ¸í ÀÌ»ó¿¡ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ÀÌ·¯ÇÑ ÆíµÎÅë À¯º´·ü Áõ°¡¿Í ¿ÀÇÇ¿ÀÀ̵åÀÇ ¸¸¿¬Àº ¹Ú¸· Á¦Á¦ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
°Ô´Ù°¡ ¹Ú¸· Á¦Á¦ ¿¬±¸°³¹ß ÅõÀÚ È®´ë°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 11¿ù, ÁÙ¶óŸ½Å Çʸ§Àº ¹Ú¸· Á¦Á¦ ±â¼ú °³¹ßÀ» À§ÇØ ÃÑ 487¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, Ãʱâ ÅõÀÚ ÀÚ±ÝÀ» Á¶´ÞÇß½À´Ï´Ù. ÀÌ ÅõÀÚ·Î Á¶´ÞÇÑ ÀÚ±ÝÀº ½Ã°£´ç 1,000ȸ ÀÌ»ó »ý¹°ÇÐÀû Á¦Á¦¸¦ žÀçÇÑ ¹Ú¸·À» Á¦ÀÛÇÒ ¼ö ÀÖ´Â ÆÄÀÏ·µ ½ºÄÉÀÏ Á¦Á¶ ¶óÀÎ ¼³°è ¹× ±¸ÃàÀ» Áö¿øÇß½À´Ï´Ù.
±×·¯³ª ´ëü¾àÇ° ÀÔ¼ö°¡ °¡´ÉÇϱ⠶§¹®¿¡ Á¦¾àȸ»ç ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Á¤½Å ºÐ¿ÁõÀº ¸Á»ó, ȯ°¢ ¹× ±âŸ ÀÎÁö Àå¾Ö¸¦ Ư¡À¸·Î Çϸç Á¾Á¾ Æò»ý µ¿¾È °íÅë¹Þ½À´Ï´Ù. Á¤½Å ºÐ¿ÁõÀº »ç¶÷ »ç°í, °¨Á¤, Çൿ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¸¸¼ºÀûÀÌ°í ½ÉÇÑ Á¤½Å Àå¾ÖÀÔ´Ï´Ù. ÀÌ ºÐ¾ß¸¦ ¹Ð¾îÁÖ´Â ÁÖ¿ä ¿äÀÎÀº Á¤½Å ºÐ¿Áõ SchizophreniaÀÇ À¯º´·ü Áõ°¡, ³ë³â Àα¸ Áõ°¡, ¾à¹°ÀÇ È¿°úÀûÀÎ Àü´Þ ¹æ¹ý ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù.
¿¹¸¦ µé¾î WHO µ¥ÀÌÅÍ¿¡ µû¸£¸é 2022³â Á¤½Å ºÐ¿ÁõÀº ¼¼°èÀÇ 2,400¸¸ ¸í¿¡ ¿µÇâÀ» ¹ÌÄ£´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ, 2021³â 11¿ù À¯·´ °ø°ø º¸°Ç º´¿øÀº EU Àα¸ÀÇ Á¤½Å ºÐ¿Áõ ¿¹»ó ¹ßº´·üÀº 100,000¸í ´ç ¿¬°£ 15.2¸íÀ¸·Î ¾ð±ÞÇÏ¿´½À´Ï´Ù. ÀÌ·¯ÇÑ Á¤½Å ºÐ¿Áõ À¯º´·üÀº ¹Ú¸· Á¦Á¦ ¼ö¿ä¿¡ ±â¿©ÇÏ°í °á±¹ ºÎ¹® ¼ºÀåÀ» ¹Ð¾î ¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ³ë³â Àα¸ Áõ°¡µµ ÀÌ ºÐ¾ß ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¶ÇÇÑ À¯¿£ÀÌ 2022³â ¹ßÇ¥ÇÑ º¸°í¼´Â 65¼¼ ÀÌ»ó ¼¼°èÀÇ Àα¸ Â÷ÁöÇÏ´Â ºñÀ²ÀÌ 2022³â 10%, 2050³â 16%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© »ó½ÂÇÒ °ÍÀ¸·Î ¿¹ÃøÇÏ¿´½À´Ï´Ù. Á¤½Å ºÐ¿Áõ ÁúȯÀÌ ¹ß»ýÇϱ⠽¬¿î ÀÌ·¯ÇÑ ³ë³â Àα¸ Áõ°¡´Â Á¶»ç ´ë»ó ºÎ¹® ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ Á¦Ç° ½ÂÀÎ Áõ°¡´Â Á¶»ç ´ë»ó ºÎ¹® ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 4¿ù BioXcel Therapeutics´Â ¼ºÀÎ Á¤½Å ºÐ¿Áõ ¶Ç´Â ¾ç±Ø¼º Àå¾Ö I ¶Ç´Â II¿Í °ü·ÃµÈ ÈïºÐ ±Þ¼º Ä¡·á¸¦ À§ÇÑ ¼³ÇÏ Çʸ§ÀÎ IGALM ¹Ì±¹ FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ°ÍÀº ÀÇ·á Á¾»çÀÚ °¨µ¶ÇÏ¿¡ ȯÀÚ°¡ ÀÚ°¡ Åõ¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.
µû¶ó¼ Á¤½Å ºÐ¿Áõ À¯º´·ü Áõ°¡, ³ë³â Àα¸ Áõ°¡, Á¦Ç° Çã°¡ Áõ°¡ µî À§ ¿äÀÎÀÌ ¿¬±¸ ºÎ¹® ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì´Â ¹Ú¸· Á¦Á¦ ½ÃÀå Àüü¸¦ Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀº ÁÖ¿ä ±â¾÷ Á¸Àç, Á¦¾à ¿¬±¸¿¡ »ç¿ëµÇ´Â ÷´Ü ±â¼ú, »õ·Î¿î ¾à¹° Àü´Þ ±â¼ú ¹ß°ßÀ» À§ÇÑ °³¹ß µîÀÇ ¿äÀÎ ¶§¹®ÀÔ´Ï´Ù.
Á¤½Å ºÐ¿Áõ, ÆíµÎÅë, ¿ÀÇÇ¿ÀÀ̵å Àå¾Ö¿Í °°Àº ´ë»ó Áúȯ À¯º´·ü Áõ°¡´Â ¹Ú¸· Á¦Á¦ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 6¿ù¿¡ ¹ßÇ¥µÈ NCBI ³í¹®Àº ¿ÀÇÇ¿ÀÀÌµå »ç¿ë Àå¾Ö°¡ ¹Ì±¹ ¿¬°£ 210¸¸ ¸í ÀÌ»ó¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ´Ù°í ¾ð±ÞÇÏ¿´½À´Ï´Ù. ¶ÇÇÑ, 2022³â 2¿ù¿¡ °ø°³µÈ American Migraine Foundation µ¥ÀÌÅÍ´Â 2022³â ¾à 3,000¸¸ ¸í ¹Ì±¹ÀÎÀÌ ÆíµÎÅëÀ» ¾Î°í ÀÖ´Ù°í ¾ð±ÞÇÏ¿´½À´Ï´Ù. ¸¶Âù°¡Áö·Î, 2021³â 9¿ù¿¡ ¹ßÇ¥µÈ NCBI ³í¹®Àº ij³ª´Ù ÆíµÎÅë À¯º´·üÀÌ ¿¬°£ ¾à 8.3% 10.2% ¹üÀ§ÀÎ °ÍÀ¸·Î ¾Ë·ÁÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ¹Ú¸· Á¦Á¦ ¼ö¿ä È®´ë·Î À̾îÁö´Â ´ë»ó Áúȯ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
¶ÇÇÑ ¹Ú¸· Á¦Á¦ ½ÃÀå °³Ã´À» À§ÇÑ Àü·« ÇÕÀÇ, Á¦ÈÞ, ÆÄÆ®³Ê½Ê µî ½ÃÀå Ç÷¹À̾î È°µ¿ÀÌ È°¹ßÇØÁö°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î »ý°¢µË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 3¿ù, TFF ÆÛ¸Ó½´Æ¼ÄÃÁî¿Í ijÅÍ·±Æ®´Â ¹Ú¸· µ¿°á ±â¼úÀ» ÀÌ¿ëÇÑ °ÇÁ¶ ºÐ¸» Á¦Á¦ »ý¼º, ½ÃÇè, Á¦Á¶¿¡ ´ëÇØ Çù·ÂÇÏ¿´½À´Ï´Ù. ¶ÇÇÑ 2021³â 5¿ù LTS Lohman Therapie-Systeme AG´Â Revive Therapeutics¿Í Á¤½Å Áúȯ Ä¡·á¸¦ À§ÇÑ µ¶Æ¯ÇÑ °æ±¸ ½Ç·Î½Ãºó ¹Ú¸·´ë °³¹ß ¹× Á¦Á¶ °¡¿ë¼º °è¾àÀ» ¹ßÇ¥Çß½À´Ï´Ù.
ÀÌ¿Í °°ÀÌ ´ë»ó Áúȯ À¯º´·ü »ó½Â, ¹Ú¸· Á¦Á¦ ¼ö¿ä Áõ°¡, ½ÃÀå Ç÷¹À̾î Á¸Àç µîÀÌ ÀÌ Áö¿ª ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
¹Ú¸· Á¦Á¦ ½ÃÀå °æÀïÀº Áß°£ Á¤µµÀÌ¸ç ¿©·¯ ´ëÇü ±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÇöÀç ½ÃÀåÀ» µ¶Á¡ÇÏ°í ÀÖ´Â ±â¾÷À¸·Î´Â ZIM Laboratories Limited, Aquestive Therapeutics, Indivior PLC, Tesa SE(Tesa Labtec GmbH), Pfizer, Inc., ARx, LLC., Solvay, IntelGenx. µîÀÔ´Ï´Ù.
The thin film drug market studied was projected to grow with a CAGR of nearly 9.3% over the forecast period.
COVID-19 had a significant impact on the growth of the market during the pandemic period. The demand for thin film products was notably affected due to the launch of innovative and advanced technologies for the treatment of COVID-19 disease. For instance, in May 2022, Thin Film Freezing Pharmaceuticals delivered a platform presentation with data on stabilizing and delivering antivirals, antibodies, and vaccines using thin film freezing technology in the fight against COVID-19 and other viral infections. Thus, the pandemic outbreak led to the introduction of advanced technologies, thereby significantly impacting the market growth during the pandemic period. In addition, the demand for thin film drugs is expected to remain intact owing to the rising focus on treating various chronic disorders, thereby contributing to the market's growth over the forecast period.
The increasing prevalence of diseases such as migraine, schizophrenia, opioid dependence, and others, along with rising demand for effective thin film drugsOpioid, are expected to contribute to the market's growth. For instance, the article published by DN article in January 2022 states that 1 in 7 people worldwide suffers from migraine annually, and 14.7% of people worldwide had migraine in 2021. The same source also mentioned that around 2% of the world's population suffers from chronic migraines annually. Similarly, according to the NCBI article published in June 2022, Opioid use disorders affect over 16 million people worldwide annually. Such increasing prevalence of migraine and Opioids prevalence is expected to drive the demand for thin film drugs, thereby contributing to the market's growth.
Furthermore, the growing investments in research and development of thin film drugs are expected to boost the market growth. For instance, in November 2022, Jurata Thin Film raised initial investment funds totaling USD 4.87 million to develop the thin film drug technology. The funds raised in this investment supported the design and built a pilot-scale manufacturing line capable of fabricating over 1,000 doses of biologic-loaded thin films per hour.
However, the availability of substitute drugs is expected to hinder pharmaceutical companies' market growth over the forecast period.
Schizophrenia is characterized by delusions, hallucinations, and other cognitive difficulties, often lifelong struggles. It is a chronic and severe mental disorder affecting a person's thoughts, feelings, and behavior. The major factors boosting the segment are the increasing prevalence of Schizophrenia Schizophrenia, the increasing geriatric population, and the rising demand for effective delivery method of drugs.
For instance, according to the WHO data, in 2022, schworldwideSchizophreniafects 24 million peopleSchizophreniaworldwide annually. Also, the European Journal of Public Health, in November 2021, mentioned that among the European Union population, the estimated incidence of schizophrenia was 15.2 per 100,000 persons annually. Such prevalence of Schizophrenia is expected to contribute to the demand for thin film drugs, ultimately boosting segment growth. Furthermore, the rising geriatric population is also expected to contribute to the growth of the studied segment. Additionally, the report published by the UN in 2022 mentioned that the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Such a rising geriatric population prone to develop schizophrenia disorders is expected to drive the growth of the studied segment over the forecast period.
Also, the increasing product approvals are expected to drive the growth of the studied segment. For instance, in April 2022, BioXcel Therapeutics received US FDA approval for the IGALM, a sublingual film for the acute treatment of agitation associated with Schizophrenia or bipolar I or II disorder in adults. This can be self-administrated by patients under the supervision of a healthcare provider.
Thus the factors mentioned above, such rising prevalence of Schizophrenia, the rising geriatric population, and increasing product approvals, are expected to drive the growth of the studied segment during the forecast period.
North America is expected to dominate the overall thin film drug market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, advanced technologies used in pharmaceutical research, and development for the discovery of novel drug delivery techniques.
The increasing prevalence of target diseases, such as schizophrenia, migraine, opioid disorders, and others is expected to drive the demand for thin film drugs, thereby contributing to the growth of the market. For instance, the NCBI article published in June 2022, mentioned that opioid use disorders affected over 2.1 million in the United States annually. Also, American Migraine Foundation data published in February 2022, mentioned that approximately 30 million Americans are affected by migraine in 2022. Likewise, the NCBI article published in September 2021, the prevalence of migraine in Canada was to be in the range of approximately 8.3% to 10.2%, annually. Such increasing prevalence of target diseases leading to the growing demand for thin film drugs is expected to contribute to the growth of the market.
Moreover, the increasing market player activities such as strategic agreements, collaborations, partnerships, and others for the development of thin film drugs, are expected to drive the growth of the market. For instance, in March 2022, TFF Pharmaceuticals and Catalent collaborated on the generation, testing, and manufacturing of dry powder formulation using thin film freezing technology. Also, in May 2021, LTS Lohman Therapie-Systeme AG announced a feasibility agreement with Revive Therapeutics to develop and manufacture a proprietary oral psilocybin thin film strip for the treatment of mental illness.
Thus, the rising prevalence of target disorders, increasing demand for thin film drugs, and presence of market players are expected to contribute to the growth of the market in this region.
The thin film drugs market is moderately competitive and consists of several major players. Some companies currently dominating the market are ZIM Laboratories Limited, Aquestive Therapeutics, Indivior PLC, Tesa SE (Tesa Labtec GmbH), Pfizer, Inc., ARx, LLC., Solvay, IntelGenx. and others.